Copyright
©The Author(s) 2021.
World J Clin Oncol. Apr 24, 2021; 12(4): 195-216
Published online Apr 24, 2021. doi: 10.5306/wjco.v12.i4.195
Published online Apr 24, 2021. doi: 10.5306/wjco.v12.i4.195
Table 4 Clinical stage of thymic epithelial tumours according to Masaoka-Koga
| Stage | Diagnostic criteria | 10-yr survival |
| I | Tumours encapsulated macroscopically and microscopically (without capsular invasion) | 84% (81%-86%) |
| II | A: Microscopic transcapsular invasion | 83% (79%-87%) |
| B: Macroscopic invasion of fatty tissue or pleural and/or pericardial adhesion | ||
| III | Macroscopic involvement of adjacent structures (pericardium, great vessels, or lung). A: With invasion of great vessels | 70% (64%-75%) |
| B: Without invasion of great vessels | ||
| IV | A: Pleural or pericardial spread | 42% (26%-58%) |
| B: Hematogenous or lymphogenic metastasis | 53% (32%-73%) |
- Citation: Rico M, Flamarique S, Casares C, García T, López M, Martínez M, Serrano J, Blanco M, Hernanz R, de Ingunza-Barón L, Marcos FJ, Couñago F. GOECP/SEOR radiotherapy guidelines for thymic epithelial tumours. World J Clin Oncol 2021; 12(4): 195-216
- URL: https://www.wjgnet.com/2218-4333/full/v12/i4/195.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i4.195